{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:26:33Z","timestamp":1794306393470,"version":"4.9.0"},"reference-count":127,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000025","name":"NIMH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["biologicalpsychiatryjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.biopsych.2026.07.009","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T14:49:04Z","timestamp":1784645344000},"page":"1168-1180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Potential of Neurosteroids for Precision Medicine in Psychiatry"],"prefix":"10.1016","volume":"100","author":[{"given":"Tauryn L.","family":"Dargan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najah L.","family":"Walton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie L.","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2026.07.009_bib1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","article-title":"Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: A systematic analysis for the Global Burden of Disease Study 2019","volume":"9","year":"2022","journal-title":"Lancet Psychiatry"},{"issue":"suppl 20","key":"10.1016\/j.biopsych.2026.07.009_bib2","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib3","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"10.1016\/j.biopsych.2026.07.009_bib4","first-page":"508","article-title":"Depression: Screening and diagnosis","volume":"98","author":"Maurer","year":"2018","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.biopsych.2026.07.009_bib5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/wps.20825","article-title":"An organization- and category-level comparison of diagnostic requirements for mental disorders in ICD-11 and DSM-5","volume":"20","author":"First","year":"2021","journal-title":"World Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1146\/annurev-clinpsy-021815-093122","article-title":"Clashing diagnostic approaches: DSM-ICD versus RDoC","volume":"12","author":"Lilienfeld","year":"2016","journal-title":"Annu Rev Clin Psychol"},{"key":"10.1016\/j.biopsych.2026.07.009_bib7","doi-asserted-by":"crossref","first-page":"8560","DOI":"10.1007\/s12144-025-07787-y","article-title":"Beyond DSM and ICD: A comprehensive look at alternative approaches to understanding PTSD","volume":"44","author":"Velasco","year":"2025","journal-title":"Curr Psychol"},{"key":"10.1016\/j.biopsych.2026.07.009_bib8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00702-017-1828-2","article-title":"Issues on the diagnosis and etiopathogenesis of mood disorders: Reconsidering DSM-5","volume":"125","author":"Ogasawara","year":"2018","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1016\/j.biopsych.2026.07.009_bib9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000315126","article-title":"Subjectivity and intersubjectivity in psychiatric diagnosis","volume":"43","author":"Fuchs","year":"2010","journal-title":"Psychopathology"},{"key":"10.1016\/j.biopsych.2026.07.009_bib10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41380-022-01891-2","article-title":"Taking subjectivity seriously: Towards a unification of phenomenology, psychiatry, and neuroscience","volume":"28","author":"Kyzar","year":"2023","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/1039856219875060","article-title":"On what basis should we select treatment in clinical psychiatry: A question too obvious to ask?","volume":"28","author":"Restifo","year":"2020","journal-title":"Australas Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.neubiorev.2012.10.005","article-title":"Neurosteroids, stress and depression: Potential therapeutic opportunities","volume":"37","author":"Zorumski","year":"2013","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.biopsych.2026.07.009_bib13","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3389\/fpsyt.2020.00432","article-title":"Biomarkers in psychiatry: Concept, definition, types and relevance to the clinical reality","volume":"11","author":"Garc\u00eda-Guti\u00e9rrez","year":"2020","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib14","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/wps.21078","article-title":"Candidate biomarkers in psychiatric disorders: State of the field","volume":"22","author":"Abi-Dargham","year":"2023","journal-title":"World Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib15","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/wps.21071","article-title":"Biomarkers in psychiatric disorders: Status quo, impediments and facilitators","volume":"22","author":"Berk","year":"2023","journal-title":"World Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib16","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41593-021-00860-2","article-title":"Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions","volume":"24","author":"Levey","year":"2021","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.biopsych.2026.07.009_bib17","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/mp.2012.21","article-title":"A mega-analysis of genome-wide association studies for major depressive disorder","volume":"18","author":"Ripke","year":"2013","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41593-018-0326-7","article-title":"Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions","volume":"22","author":"Howard","year":"2019","journal-title":"Nat Neurosci"},{"issue":"suppl 1","key":"10.1016\/j.biopsych.2026.07.009_bib19","doi-asserted-by":"crossref","first-page":"i212","DOI":"10.1093\/ijnp\/pyae059.372","article-title":"Epigenetic biomarkers of postpartum depression identify premenstrual dysphoric disorder (PMDD) and post-menopausal depression (PMD)","volume":"28","author":"Kaminsky","year":"2025","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2026.07.009_bib20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/npp.2013.238","article-title":"Seeing the future: Epigenetic biomarkers of postpartum depression","volume":"39","author":"Kaminsky","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2026.07.009_bib21","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/npp.2015.333","article-title":"Replication of epigenetic postpartum depression biomarkers and variation with hormone levels","volume":"41","author":"Osborne","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2026.07.009_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2019.112711","article-title":"DNA methylation biomarkers prospectively predict both antenatal and postpartum depression","volume":"285","author":"Payne","year":"2020","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.biopsych.2026.07.009_bib23","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.8170","article-title":"Brain structural and functional changes in patients with major depressive disorder: A literature review","volume":"7","author":"Dai","year":"2019","journal-title":"PeerJ"},{"key":"10.1016\/j.biopsych.2026.07.009_bib24","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/archgenpsychiatry.2011.60","article-title":"Structural neuroimaging studies in major depressive disorder. Meta-analysis and comparison with bipolar disorder","volume":"68","author":"Kempton","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib25","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s12264-016-0030-0","article-title":"Molecular, functional, and structural imaging of major depressive disorder","volume":"32","author":"Zhang","year":"2016","journal-title":"Neurosci Bull"},{"key":"10.1016\/j.biopsych.2026.07.009_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2024.115325","article-title":"Depression diagnosis: EEG-based cognitive biomarkers and machine learning","volume":"478","author":"Boby","year":"2025","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.biopsych.2026.07.009_bib27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.neubiorev.2019.07.021","article-title":"Depression biomarkers using non-invasive EEG: A review","volume":"105","author":"De Aguiar Neto","year":"2019","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.biopsych.2026.07.009_bib28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s44184-023-00038-7","article-title":"Technical and clinical considerations for electroencephalography-based biomarkers for major depressive disorder","volume":"2","author":"Simmatis","year":"2023","journal-title":"Npj Ment Health Res"},{"key":"10.1016\/j.biopsych.2026.07.009_bib29","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41587-019-0397-3","article-title":"An electroencephalographic signature predicts antidepressant response in major depression","volume":"38","author":"Wu","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.biopsych.2026.07.009_bib30","article-title":"Identifying EEG biomarkers of depression with novel explainable deep learning architectures","author":"Ellis","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.biopsych.2026.07.009_bib31","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.6653","article-title":"Evaluation of a machine learning model based on pretreatment symptoms and electroencephalographic features to predict outcomes of antidepressant treatment in adults with depression: A prespecified secondary analysis of a randomized clinical trial","volume":"3","author":"Rajpurkar","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.biopsych.2026.07.009_bib32","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41398-022-02064-z","article-title":"Predicting treatment response using EEG in major depressive disorder: A machine-learning meta-analysis","volume":"12","author":"Watts","year":"2022","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib33","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2147\/NDT.S114542","article-title":"Biomarkers for depression: Recent insights, current challenges and future prospects","volume":"13","author":"Strawbridge","year":"2017","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.biopsych.2026.07.009_bib34","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41392-024-01738-y","article-title":"Major depressive disorder: Hypothesis, mechanism, prevention and treatment","volume":"9","author":"Cui","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.biopsych.2026.07.009_bib35","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1038\/s41380-020-0645-4","article-title":"An integrated meta-analysis of peripheral blood metabolites and biological functions in major depressive disorder","volume":"26","author":"Pu","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib36","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3389\/fpsyt.2020.00667","article-title":"A novel network pharmacology strategy to decode metabolic biomarkers and targets interactions for depression","volume":"11","author":"Gao","year":"2020","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib37","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3390\/genes16050487","article-title":"Advancing depression management through biomarker discovery with a focus on genetic and epigenetic aspects: A comprehensive study on neurobiological, neuroendocrine, metabolic, and inflammatory pathways","volume":"16","author":"Milic","year":"2025","journal-title":"Genes"},{"key":"10.1016\/j.biopsych.2026.07.009_bib38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41386-023-01626-z","article-title":"Neurosteroids: Mechanistic considerations and clinical prospects","volume":"49","author":"Maguire","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2026.07.009_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2025.106119","article-title":"New directions in neurosteroid therapeutics in neuropsychiatry","volume":"172","author":"Zorumski","year":"2025","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.biopsych.2026.07.009_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ynstr.2020.100215","article-title":"Allopregnanolone: From molecular pathophysiology to therapeutics. A historical perspective","volume":"12","author":"Paul","year":"2020","journal-title":"Neurobiol Stress"},{"key":"10.1016\/j.biopsych.2026.07.009_bib41","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000097879","article-title":"Neuroactive steroids in depression and anxiety disorders: Clinical studies","volume":"84","author":"Eser","year":"2006","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.biopsych.2026.07.009_bib42","series-title":"Handbook of Hormones","first-page":"537","article-title":"Neurosteroids","author":"Tsutsui","year":"2016"},{"key":"10.1016\/j.biopsych.2026.07.009_bib43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/B978-0-444-53630-3.00008-7","article-title":"Neurosteroids: Endogenous role in the human brain and therapeutic potentials","volume":"186","author":"Reddy","year":"2010","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.biopsych.2026.07.009_bib44","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.neuroscience.2011.03.025","article-title":"Neuroactive steroids in affective disorders: Target for novel antidepressant or anxiolytic drugs?","volume":"191","author":"Sch\u00fcle","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopsych.2026.07.009_bib45","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/sj.npp.1300952","article-title":"Neuroactive steroids are altered in schizophrenia and bipolar disorder: Relevance to pathophysiology and therapeutics","volume":"31","author":"Marx","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2026.07.009_bib46","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0006-3223(98)00070-5","article-title":"Can the antidysphoric and anxiolytic profiles of selective serotonin reuptake inhibitors be related to their ability to increase brain 3 alpha, 5 alpha-tetrahydroprogesterone (allopregnanolone) availability?","volume":"44","author":"Guidotti","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib47","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrn1703","article-title":"Neurosteroids: Endogenous regulators of the GABA(A) receptor","volume":"6","author":"Belelli","year":"2005","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.biopsych.2026.07.009_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2024.105558","article-title":"Emerging evidence for endogenous neurosteroid modulation of pro-inflammatory and anti-inflammatory pathways that impact neuropsychiatric disease","volume":"158","author":"Morrow","year":"2024","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.biopsych.2026.07.009_bib49","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13226","article-title":"Biomarkers and treatments for mood disorders encompassing the neurosteroid and endocannabinoid systems","volume":"35","author":"Pinna","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.biopsych.2026.07.009_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108299","article-title":"Neurosteroids (allopregnanolone) and alcohol use disorder: From mechanisms to potential pharmacotherapy","volume":"240","author":"Gatta","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.biopsych.2026.07.009_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.yfrne.2023.101119","article-title":"The role of neurosteroids in posttraumatic stress disorder and alcohol use disorder: A review of 10 years of clinical literature and treatment implications","volume":"73","author":"Peltier","year":"2024","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.biopsych.2026.07.009_bib52","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0165-6147(00)89058-6","article-title":"Neurosteroids and GABAA receptor function","volume":"16","author":"Lambert","year":"1995","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.biopsych.2026.07.009_bib53","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pharmthera.2007.05.006","article-title":"Neurosteroids in the context of stress: Implications for depressive disorders","volume":"116","author":"Girdler","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.biopsych.2026.07.009_bib54","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0006-3223(00)01044-1","article-title":"Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder","volume":"49","author":"Girdler","year":"2001","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib55","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.biopsycho.2005.02.007","article-title":"Histories of depression, allopregnanolone responses to stress, and premenstrual symptoms in women","volume":"71","author":"Klatzkin","year":"2006","journal-title":"Biol Psychol"},{"key":"10.1016\/j.biopsych.2026.07.009_bib56","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1001\/archpsyc.60.2.161","article-title":"Induced panic attacks shift gamma-aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: Preliminary results","volume":"60","author":"Str\u00f6hle","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib57","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1073\/pnas.95.6.3239","article-title":"Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine","volume":"95","author":"Uzunova","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.biopsych.2026.07.009_bib58","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.biopsych.2006.03.026","article-title":"Decreased cerebrospinal fluid allopregnanolone levels in women with posttraumatic stress disorder","volume":"60","author":"Rasmusson","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib59","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0006-3223(98)00328-X","article-title":"Concentrations of 3 alpha-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery","volume":"45","author":"Str\u00f6hle","year":"1999","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib60","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.pneurobio.2013.09.003","article-title":"The role of allopregnanolone in depression and anxiety","volume":"113","author":"Sch\u00fcle","year":"2014","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.biopsych.2026.07.009_bib61","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jad.2024.01.268","article-title":"The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials","volume":"351","author":"Clayton","year":"2024","journal-title":"J Affect Disord"},{"key":"10.1016\/j.biopsych.2026.07.009_bib62","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1176\/ajp.155.7.910","article-title":"Effects of antidepressant treatment on neuroactive steroids in major depression","volume":"155","author":"Romeo","year":"1998","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib63","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1007\/s00213-014-3567-5","article-title":"5\u03b1-reductase type I expression is downregulated in the prefrontal cortex\/Brodmann\u2019s area 9 (BA9) of depressed patients","volume":"231","author":"Agis-Balboa","year":"2014","journal-title":"Psychopharmacol (Berl)"},{"key":"10.1016\/j.biopsych.2026.07.009_bib64","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1111\/bph.13843","article-title":"Neurosteroid biosynthesis down-regulation and changes in GABAA receptor subunit composition: A biomarker axis in stress-induced cognitive and emotional impairment","volume":"174","author":"Locci","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.biopsych.2026.07.009_bib65","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.psyneuen.2011.08.004","article-title":"A history of depression in women is associated with an altered GABAergic neuroactive steroid profile","volume":"37","author":"Girdler","year":"2012","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.biopsych.2026.07.009_bib66","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/sj.mp.4001782","article-title":"Influence of mirtazapine on plasma concentrations of neuroactive steroids in major depression and on 3\u03b1-hydroxysteroid dehydrogenase activity","volume":"11","author":"Sch\u00fcle","year":"2006","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib67","doi-asserted-by":"crossref","first-page":"13512","DOI":"10.1073\/pnas.96.23.13512","article-title":"Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes","volume":"96","author":"Griffin","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.biopsych.2026.07.009_bib68","author":"Gartlehner"},{"key":"10.1016\/j.biopsych.2026.07.009_bib69","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/sj.npp.1300684","article-title":"Plasma concentrations of neuroactive steroids before and after electroconvulsive therapy in major depression","volume":"30","author":"Baghai","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2026.07.009_bib70","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1186\/s12888-024-06167-3","article-title":"Allopregnanolone and progesterone in relation to a single electroconvulsive therapy seizure and subsequent clinical outcome: An observational cohort study","volume":"24","author":"Th\u00f6rnblom","year":"2024","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib71","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/s41398-024-02942-8","article-title":"Altered blood parameters in \u201cmajor depression\u201d patients receiving repetitive transcranial magnetic stimulation (rTMS) therapy: A randomized case-control study","volume":"14","author":"Ozkan","year":"2024","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib72","doi-asserted-by":"crossref","DOI":"10.1111\/jne.12792","article-title":"Neurobehavioural complications of sleep deprivation: Shedding light on the emerging role of neuroactive steroids","volume":"32","author":"Frau","year":"2020","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.biopsych.2026.07.009_bib73","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1038\/npp.2017.13","article-title":"The neurosteroidogenic enzyme 5\u03b1-reductase mediates psychotic-like complications of sleep deprivation","volume":"42","author":"Frau","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2026.07.009_bib74","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1046\/j.1471-4159.2000.0750732.x","article-title":"Social isolation-induced decreases in both the abundance of neuroactive steroids and GABA(A) receptor function in rat brain","volume":"75","author":"Serra","year":"2000","journal-title":"J Neurochem"},{"key":"10.1016\/j.biopsych.2026.07.009_bib75","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1007\/s00213-015-4046-3","article-title":"DHEA metabolism to the neurosteroid androsterone: A possible mechanism of DHEA\u2019s antidepressant action","volume":"232","author":"Ben Dor","year":"2015","journal-title":"Psychopharmacol (Berl)"},{"key":"10.1016\/j.biopsych.2026.07.009_bib76","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jad.2022.09.143","article-title":"Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: Pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the Hummingbird clinical program","volume":"320","author":"Epperson","year":"2023","journal-title":"J Affect Disord"},{"key":"10.1016\/j.biopsych.2026.07.009_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.ynstr.2019.100198","article-title":"Allopregnanolone-based treatments for postpartum depression: Why\/how do they work?","volume":"11","author":"Walton","year":"2019","journal-title":"Neurobiol Stress"},{"key":"10.1016\/j.biopsych.2026.07.009_bib78","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3109\/09540269609037816","article-title":"Rates and risk of postpartum depression\u2014A meta-analysis","volume":"8","author":"O\u2019hara","year":"1996","journal-title":"Int Rev Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib79","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/01.AOG.0000183597.31630.db","article-title":"Perinatal depression: A systematic review of prevalence and incidence","volume":"106","author":"Gavin","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.biopsych.2026.07.009_bib80","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00737-005-0080-1","article-title":"Prevalence of suicidality during pregnancy and the postpartum","volume":"8","author":"Lindahl","year":"2005","journal-title":"Arch Womens Ment Health"},{"key":"10.1016\/j.biopsych.2026.07.009_bib81","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1210\/jcem.85.7.6675","article-title":"Serum allopregnanolone levels in pregnant women: Changes during pregnancy, at delivery, and in hypertensive patients","volume":"85","author":"Luisi","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.biopsych.2026.07.009_bib82","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/s41380-024-02747-7","article-title":"Peripartum allopregnanolone blood concentrations and depressive symptoms: A systematic review and individual participant data meta-analysis","volume":"30","author":"Schoretsanitis","year":"2025","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib83","article-title":"Steroid hormone sensitivity in reproductive mood disorders: On the role of the GABAA receptor complex and stress during hormonal transitions","volume":"7","author":"Schweizer-Schubert","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.biopsych.2026.07.009_bib84","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.neuron.2008.06.019","article-title":"GABA(A)R plasticity during pregnancy: Relevance to postpartum depression","volume":"59","author":"Maguire","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.biopsych.2026.07.009_bib85","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.psyneuen.2017.12.003","article-title":"Inability to suppress the stress-induced activation of the HPA axis during the peripartum period engenders deficits in postpartum behaviors in mice","volume":"90","author":"Mel\u00f3n","year":"2018","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.biopsych.2026.07.009_bib86","first-page":"77","article-title":"Serum allopregnanolone in women with postpartum \u201cblues.\u201d","volume":"97","author":"Nappi","year":"2001","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.biopsych.2026.07.009_bib87","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41386-025-02052-z","article-title":"Neuroactive steroid biosynthesis during pregnancy predicts future postpartum depression: A role for the 3\u03b1 and\/or 3\u03b2-HSD neurosteroidogenic enzymes?","volume":"50","author":"Osborne","year":"2025","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2026.07.009_bib88","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.146","article-title":"The steroid metabolome in women with premenstrual dysphoric disorder during GnRH agonist-induced ovarian suppression: Effects of estradiol and progesterone addback","volume":"7","author":"Nguyen","year":"2017","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib89","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s00213-016-4258-1","article-title":"Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls-a pilot study","volume":"233","author":"Timby","year":"2016","journal-title":"Psychopharmacol (Berl)"},{"key":"10.1016\/j.biopsych.2026.07.009_bib90","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1192\/bjp.2025.103","article-title":"Neurosteroids and premenstrual dysphoric disorder","volume":"229","author":"Bixo","year":"2025","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib91","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/npp.2015.246","article-title":"5\u03b1-reductase inhibition prevents the luteal phase increase in plasma allopregnanolone levels and mitigates symptoms in women with premenstrual dysphoric disorder","volume":"41","author":"Martinez","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2026.07.009_bib92","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.yfrne.2006.02.003","article-title":"Gonadal steroid regulation of mood: The lessons of premenstrual syndrome","volume":"27","author":"Rubinow","year":"2006","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.biopsych.2026.07.009_bib93","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.coph.2008.12.006","article-title":"SSRIs act as selective brain steroidogenic stimulants (SBSSs) at low doses that are inactive on 5-HT reuptake","volume":"9","author":"Pinna","year":"2009","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.biopsych.2026.07.009_bib94","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1038\/npp.2014.138","article-title":"A randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar depression","volume":"39","author":"Brown","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"suppl 1","key":"10.1016\/j.biopsych.2026.07.009_bib95","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0165-0327(14)70004-7","article-title":"Differential diagnosis of bipolar disorder and major depressive disorder","volume":"169","author":"Hirschfeld","year":"2014","journal-title":"J Affect Disord"},{"key":"10.1016\/j.biopsych.2026.07.009_bib96","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/01.jcp.0000229483.52955.ec","article-title":"Increased neuroactive steroid concentrations in women with bipolar disorder or major depressive disorder","volume":"26","author":"Hardoy","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2026.07.009_bib97","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1017\/S1092852900017120","article-title":"Improving the prediction of treatment response in depression: Integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures","volume":"13","author":"Kemp","year":"2008","journal-title":"CNS Spectr"},{"issue":"suppl 16","key":"10.1016\/j.biopsych.2026.07.009_bib98","first-page":"18","article-title":"Clinical features of treatment-resistant depression","volume":"62","author":"Kornstein","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib99","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0140-6736(17)31264-3","article-title":"Brexanolone (SAGE-547 injection) in post-partum depression: A randomised controlled trial","volume":"390","author":"Kanes","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2026.07.009_bib100","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40263-019-00672-w","article-title":"Using matching-adjusted indirect comparisons and network meta-analyses to compare efficacy of brexanolone injection with selective serotonin reuptake inhibitors for treating postpartum depression","volume":"33","author":"Cooper","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.biopsych.2026.07.009_bib101","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2576","article-title":"Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression","volume":"32","author":"Kanes","year":"2017","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.biopsych.2026.07.009_bib102","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00213-024-06611-y","article-title":"The efficacy and safety of Zuranolone for treatment of depression: A systematic review and meta-analysis","volume":"241","author":"Fayoud","year":"2024","journal-title":"Psychopharmacol (Berl)"},{"key":"10.1016\/j.biopsych.2026.07.009_bib103","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR\u2217D: Implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib104","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1517\/13543780902880850","article-title":"Current investigational drugs for major depression","volume":"18","author":"Kulkarni","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.biopsych.2026.07.009_bib105","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0140-6736(18)31551-4","article-title":"Brexanolone injection in post-partum depression: Two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"392","author":"Meltzer-Brody","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2026.07.009_bib106","article-title":"FDA approves first oral drug for postpartum depression, but rejects it for major depressive disorder","volume":"22","author":"Mullard","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.biopsych.2026.07.009_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2021.105426","article-title":"A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder","volume":"133","author":"B\u00e4ckstr\u00f6m","year":"2021","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.biopsych.2026.07.009_bib108","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.psyneuen.2017.02.031","article-title":"Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)-A randomized controlled trial","volume":"80","author":"Bixo","year":"2017","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.biopsych.2026.07.009_bib109","first-page":"617","article-title":"Diagnosis and management of generalized anxiety disorder and panic disorder in adults","volume":"91","author":"Locke","year":"2015","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.biopsych.2026.07.009_bib110","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1176\/jnp.13.3.396","article-title":"Neuroactive steroid levels in patients with generalized anxiety disorder","volume":"13","author":"Semeniuk","year":"2001","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.biopsych.2026.07.009_bib111","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/0091-3057(94)90197-X","article-title":"Pregnenolone and pregnenolone sulfate, alone and with ethanol, in mice on the plus-maze","volume":"48","author":"Melchior","year":"1994","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.biopsych.2026.07.009_bib112","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.cpr.2011.07.006","article-title":"Anxiety sensitivity, the menstrual cycle, and panic disorder: A putative neuroendocrine and psychological interaction","volume":"31","author":"Nillni","year":"2011","journal-title":"Clin Psychol Rev"},{"key":"10.1016\/j.biopsych.2026.07.009_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2025.106085","article-title":"Neuroactive steroids and the pathophysiology of PTSD: Biomarkers for treatment targeting","volume":"172","author":"Pinna","year":"2025","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.biopsych.2026.07.009_bib114","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fnbeh.2019.00114","article-title":"Animal models of PTSD: The socially isolated mouse and the biomarker role of allopregnanolone","volume":"13","author":"Pinna","year":"2019","journal-title":"Front Behav Neurosci"},{"key":"10.1016\/j.biopsych.2026.07.009_bib115","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1007\/s00213-017-4649-y","article-title":"A randomized controlled trial of ganaxolone in posttraumatic stress disorder","volume":"234","author":"Rasmusson","year":"2017","journal-title":"Psychopharmacol (Berl)"},{"key":"10.1016\/j.biopsych.2026.07.009_bib116","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.psyneuen.2018.11.027","article-title":"Relationships between cerebrospinal fluid GABAergic neurosteroid levels and symptom severity in men with PTSD","volume":"102","author":"Rasmusson","year":"2019","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.biopsych.2026.07.009_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.ynstr.2020.100225","article-title":"Associations between PTSD-Related extinction retention deficits in women and plasma steroids that modulate brain GABAA and NMDA receptor activity","volume":"13","author":"Pineles","year":"2020","journal-title":"Neurobiol Stress"},{"key":"10.1016\/j.biopsych.2026.07.009_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.comppsych.2023.152438","article-title":"The associations of hair cortisol and DHEA with posttraumatic stress disorder symptoms in refugees","volume":"129","author":"De Graaff","year":"2024","journal-title":"Compr Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib119","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/jts.20372","article-title":"Low cortisol, high DHEA, and high levels of stimulated TNF-\u03b1, and IL-6 in women with PTSD","volume":"21","author":"Gill","year":"2008","journal-title":"J Trauma Stress"},{"key":"10.1016\/j.biopsych.2026.07.009_bib120","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1176\/appi.ajp.162.2.380","article-title":"Neuroactive steroids and suicidality in posttraumatic stress disorder","volume":"162","author":"Butterfield","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib121","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/0006-8993(86)91500-3","article-title":"Anxiolytic activity of an endogenous adrenal steroid","volume":"398","author":"Crawley","year":"1986","journal-title":"Brain Res"},{"key":"10.1016\/j.biopsych.2026.07.009_bib122","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.euroneuro.2007.04.005","article-title":"The influence of clozapine treatment and other antipsychotics on the 18 kDa translocator protein, formerly named the peripheral-type benzodiazepine receptor, and steroid production","volume":"18","author":"Danovich","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2026.07.009_bib123","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1038\/s41380-022-01561-3","article-title":"Translocator protein (18kDa) TSPO: A new diagnostic or therapeutic target for stress-related disorders?","volume":"27","author":"Rupprecht","year":"2022","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2026.07.009_bib124","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.bbi.2023.07.023","article-title":"TSPO PET brain inflammation imaging: A transdiagnostic systematic review and meta-analysis of 156 case-control studies","volume":"113","author":"De Picker","year":"2023","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.biopsych.2026.07.009_bib125","series-title":"5\u03b1-Reductase Deficiency","author":"Sharma","year":"2026"},{"key":"10.1016\/j.biopsych.2026.07.009_bib126","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.fertnstert.2011.05.040","article-title":"Idiopathic hirsutism: Local and peripheral expression of aromatase (CYP19A) and 5\u03b1-reductase genes (SRD5A1 and SRD5A2)","volume":"96","author":"Caglayan","year":"2011","journal-title":"Fertil Steril"},{"key":"10.1016\/j.biopsych.2026.07.009_bib127","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1530\/EJE-20-1077","article-title":"Peripheral blood mononuclear cells preferentially activate 11-oxygenated androgens","volume":"184","author":"Schiffer","year":"2021","journal-title":"Eur J Endocrinol"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322326014010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322326014010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T09:39:23Z","timestamp":1794303563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322326014010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":127,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0006322326014010"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2026.07.009","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential of Neurosteroids for Precision Medicine in Psychiatry","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopsych.2026.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Society of Biological Psychiatry.","name":"copyright","label":"Copyright"}]}}